Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.